Decline In Ad Letters Does Not Signal Leniency By FDA, Agency Says
Executive Summary
Although FDA is issuing fewer warning letters, those issued are more likely to signal a potential enforcement action, FDA Associate Commissioner Peter Pitts suggested during the DTC National Conference & Expo in Boston March 30
You may also be interested in...
Pfizer Zyrtec-D promotions
Professional sales aid and product website for Zyrtec-D (certirizine/pseudoephedrine) fail to include contraindications and warnings regarding the antihistamine's pseudoephedrine component, April 22 1FDA ad division letter says. Associate Commissioner Peter Pitts recently pointed to Pfizer's website as a model for internet promotion (2"The Pink Sheet" April 5, 2004, p. 18)...
Pfizer Zyrtec-D promotions
Professional sales aid and product website for Zyrtec-D (certirizine/pseudoephedrine) fail to include contraindications and warnings regarding the antihistamine's pseudoephedrine component, April 22 1FDA ad division letter says. Associate Commissioner Peter Pitts recently pointed to Pfizer's website as a model for internet promotion (2"The Pink Sheet" April 5, 2004, p. 18)...
Patient Retention Ads Should Be Larger Part Of DTC Spend, Consultant Says
Pharmaceutical companies should devote more of their advertising budgets to patient retention and compliance, DTC Perspectives CEO Robert Ehrlich said